These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 31775871)
1. Study partner types and prediction of cognitive performance: implications to preclinical Alzheimer's trials. Nuño MM; Gillen DL; Grill JD; Alzheimers Res Ther; 2019 Nov; 11(1):92. PubMed ID: 31775871 [TBL] [Abstract][Full Text] [Related]
2. Participant and study partner prediction and identification of cognitive impairment in preclinical Alzheimer's disease: study partner vs. participant accuracy. Ryan MM; Grill JD; Gillen DL; Alzheimers Res Ther; 2019 Oct; 11(1):85. PubMed ID: 31627738 [TBL] [Abstract][Full Text] [Related]
4. Longitudinal Trajectories of the Cognitive Function Index in the A4 Study. Amariglio RE; Grill JD; Rentz DM; Marshall GA; Donohue MC; Liu A; Aisen PS; Sperling RA J Prev Alzheimers Dis; 2024; 11(4):838-845. PubMed ID: 39044492 [TBL] [Abstract][Full Text] [Related]
5. Item-Level Investigation of Participant and Study Partner Report on the Cognitive Function Index from the A4 Study Screening Data. Amariglio RE; Sikkes SAM; Marshall GA; Buckley RF; Gatchel JR; Johnson KA; Rentz DM; Donohue MC; Raman R; Sun CK; Yaari R; Holdridge KC; Sims JR; Grill JD; Aisen PS; Sperling RA J Prev Alzheimers Dis; 2021; 8(3):257-262. PubMed ID: 34101781 [TBL] [Abstract][Full Text] [Related]
6. Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument. Amariglio RE; Donohue MC; Marshall GA; Rentz DM; Salmon DP; Ferris SH; Karantzoulis S; Aisen PS; Sperling RA; JAMA Neurol; 2015 Apr; 72(4):446-54. PubMed ID: 25706191 [TBL] [Abstract][Full Text] [Related]
8. Effect of study partner on the conduct of Alzheimer disease clinical trials. Grill JD; Raman R; Ernstrom K; Aisen P; Karlawish J Neurology; 2013 Jan; 80(3):282-8. PubMed ID: 23255824 [TBL] [Abstract][Full Text] [Related]
9. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM; J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495 [TBL] [Abstract][Full Text] [Related]
10. Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial. Papp KV; Rofael H; Veroff AE; Donohue MC; Wang S; Randolph C; Grober E; Brashear HR; Novak G; Ernstrom K; Raman R; Aisen PS; Sperling R; Romano G; Henley D J Prev Alzheimers Dis; 2022; 9(2):255-261. PubMed ID: 35542998 [TBL] [Abstract][Full Text] [Related]
11. Predictors of who Serves as an Alzheimer's Disease Research Participant's Study Partner and the Impact of their Relationship on Study Partners' Reports on Participants. Stites SD; Largent EA; Gill J; Gurian A; Harkins K; Karlawish J Res Aging; 2022; 44(9-10):734-746. PubMed ID: 35324354 [No Abstract] [Full Text] [Related]
12. Is Reluctance to Share Alzheimer's Disease Biomarker Status with a Study Partner a Barrier to Preclinical Trial Recruitment? Cox CG; Ryan MM; Gillen DL; Grill JD J Prev Alzheimers Dis; 2021; 8(1):52-58. PubMed ID: 33336225 [TBL] [Abstract][Full Text] [Related]
14. Profiles of Cognitive Change in Preclinical and Prodromal Alzheimer's Disease Using Change-Point Analysis. Williams OA; An Y; Armstrong NM; Kitner-Triolo M; Ferrucci L; Resnick SM J Alzheimers Dis; 2020; 75(4):1169-1180. PubMed ID: 32390623 [TBL] [Abstract][Full Text] [Related]
15. Measuring instrumental activities of daily living in non-demented elderly: a comparison of the new performance-based Harvard Automated Phone Task with other functional assessments. Marshall GA; Aghjayan SL; Dekhtyar M; Locascio JJ; Jethwani K; Amariglio RE; Czaja SJ; Loewenstein DA; Johnson KA; Sperling RA; Rentz DM Alzheimers Res Ther; 2019 Jan; 11(1):4. PubMed ID: 30630529 [TBL] [Abstract][Full Text] [Related]
16. Minimizing the Sample Sizes of Clinical Trials on Preclinical and Early Symptomatic Stage of Alzheimer Disease. Luo J; Weng H; Morris JC; Xiong C J Prev Alzheimers Dis; 2018; 5(2):110-119. PubMed ID: 29616704 [TBL] [Abstract][Full Text] [Related]
17. The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD): Experience from the First 3 Years. Walter S; Langford OG; Clanton TB; Jimenez-Maggiora GA; Raman R; Rafii MS; Shaffer EJ; Sperling RA; Cummings JL; Aisen PS J Prev Alzheimers Dis; 2020; 7(4):234-241. PubMed ID: 32920625 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease. Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255 [TBL] [Abstract][Full Text] [Related]
20. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL; Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]